Clinical Aspects of the Differential Diagnosis of Parkinson’s Disease and Parkinsonism

키워드

참고문헌 (107)

1. Kalia LV, "α-Synuclein and Lewy pathology in Parkinson’s disease", Curr Opin Neurol, 28, pp.375~381 (2015)
2. Sveinbjornsdottir S, "The clinical symptoms of Parkinson’s disease", J Neurochem, 139(Suppl 1), pp.318~324 (2016)
3. Kalia LV, "Parkinson’s disease", Lancet, 386, pp.896~912 (2015)
4. Gao LL, "Levodopa effect on basal ganglia motor circuit in Parkinson’s disease", CNS Neurosci Ther, 23, pp.76~86 (2017)
5. Menšíková K, "Atypical parkinsonism of progressive supranuclear palsy-parkinsonism(PSP-P)phenotype with rare variants in FBXO7and VPS35 genes associated with Lewy body pathology", Acta Neuropathol, 137, pp.171~173 (2019)
6. Keener AM, "Parkinsonism", Semin Neurol, 36, pp.330~334 (2016)
7. Schnaberth G, ""Parkinson plus. "Multisystem involvement in Parkinson disease", Fortschr Med, 104, pp.205~212 (1986)
8. Olfati N, "Progress in the treatment of Parkinson-Plus syndromes", Parkinsonism Relat Disord, 59, pp.101~110 (2019)
9. Seppi K, "MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice", Parkinsonism Relat Disord, 13(Suppl 3), pp.S400~S405 (2007)
10. Chougar L, "The role of magnetic resonance imaging for the diagnosis of atypical parkinsonism", Front Neurol, 11, pp.665~ (2020)
11. Brajkovic L, "The utility of FDG-PET in the differential diagnosis of Parkinsonism", Neurol Res, 39, pp.675~684 (2017)
12. Weber WE, "Role of DAT-SPECT in diagnostic work-up of Parkinsonism", Mov Disord, 23, pp.774~ (2008)
13. Williams DR, "Parkinsonian syndromes", Continuum(Minneap Minn), 19(5 Movement Disorders), pp.1189~1212 (2013)
14. Herzberg L, "An essay on the shaking palsy : reviews and notes on the journals in which they appeared", Mov Disord, 5, pp.162~166 (1990)
15. Albin RL, "The functional anatomy of basal ganglia disorders", Trends Neurosci, 12, pp.366~375 (1989)
16. DeLong MR, "Primate models of movement disorders of basal ganglia origin", Trends Neurosci, 13, pp.281~285 (1990)
17. Rinne JO, "Nigral degeneration in Parkinson’s disease", Mov Disord, 8(Suppl 1), pp.S31~S35 (1993)
18. Simuni T, "How stable are Parkinson’s disease subtypes in de novo patients : analysis of the PPMI cohort?", Parkinsonism Relat Disord, 28, pp.62~67 (2016)
19. Foltynie T, "The heterogeneity of idiopathic Parkinson’s disease", J Neurol, 249, pp.138~145 (2002)
20. Schapira AH, "Parkinson disease : Parkinson disease clinical subtypes and their implications", Nat Rev Neurol, 7, pp.247~248 (2011)
21. van der Heeden JF, "Postural instability and gait are associated with severity and prognosis of Parkinson disease", Neurology, 86, pp.2243~2250 (2016)
22. Nutt JG, "Freezing of gait : moving forward on a mysterious clinical phenomenon", Lancet Neurol, 10, pp.734~744 (2011)
23. Hoehn MM, "Parkinsonism : onset, progression and mortality", Neurology, 17, pp.427~442 (1967)
24. Martínez-Martín P, "Unified Parkinson’s Disease Rating Scale characteristics and structure", Mov Disord, 9, pp.76~83 (1994)
25. Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease, "The Unified Parkinson’s Disease Rating Scale(UPDRS) : status and recommendations", Mov Disord, 18, pp.738~750 (2003)
26. Goetz CG, "Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale(MDS-UPDRS) : process, format, and clinimetric testing plan", Mov Disord, 22, pp.41~47 (2007)
27. Lee HM, "Many faces of Parkinson’s disease : non-motor symptoms of Parkinson’s disease", J Mov Disord, 8, pp.92~97 (2015)
28. Schapira AHV, "Non-motor features of Parkinson disease", Nat Rev Neurosci, 18, pp.435~450 (2017)
29. Spillantini MG, "Alpha-synuclein in Lewy bodies", Nature, 388, pp.839~840 (1997)
30. Dickson DW, "Parkinson’s disease and parkinsonism : neuropathology", Cold Spring Harb Perspect Med, 2, pp.a009258~ (2012)
31. Braak H, "Staging of brain pathology related to sporadic Parkinson’s disease", Neurobiol Aging, 24, pp.197~211 (2003)
32. Mahlknecht P, "The concept of prodromal Parkinson’s disease", J Parkinsons Dis, 5, pp.681~697 (2015)
33. Hughes AJ, "Accuracy of clinical diagnosis of idiopathic Parkinson’s disease : a clinico-pathological study of 100 cases", J Neurol Neurosurg Psychiatry, 55, pp.181~184 (1992)
34. Poewe W, "Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice", Mov Disord, 18(Suppl 7), pp.S16~S21 (2003)
35. 진소영, "Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging", Nuclear Medicine and Molecular Imaging, 47(1), pp.44~51 (2013), 대한핵의학회
36. Gibb WR, "The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease", J Neurol Neurosurg Psychiatry, 51, pp.745~752 (1988)
37. Postuma RB, "MDS clinical diagnostic criteria for Parkinson’s disease", Mov Disord, 30, pp.1591~1601 (2015)
38. Postuma RB, "Validation of the MDS clinical diagnostic criteria for Parkinson’s disease", Mov Disord, 33, pp.1601~1608 (2018)
39. Selikhova M, "A clinico-pathological study of subtypes in Parkinson’s disease", Brain, 132(Pt 11), pp.2947~2957 (2009)
40. Fereshtehnejad SM, "New clinical subtypes of Parkinson disease and their longitudinal progression : a prospective cohort comparison with other phenotypes", JAMA Neurol, 72, pp.863~873 (2015)
41. Fereshtehnejad SM, "Clinical criteria for subtyping Parkinson’s disease : biomarkers and longitudinal progression", Brain, 140, pp.1959~1976 (2017)
42. Rajput AH, "Baseline motor findings and Parkinson disease prognostic subtypes", Neurology, 89, pp.138~143 (2017)
43. Berg D, "MDS research criteria for prodromal Parkinson’s disease", Mov Disord, 30, pp.1600~1611 (2015)
44. Pilotto A, "Application of the movement disorder society prodromal Parkinson’s disease research criteria in 2 independent prospective cohorts", Mov Disord, 32, pp.1025~1034 (2017)
45. Heinzel S, "Update of the MDS research criteria for prodromal Parkinson’s disease", Mov Disord, 34, pp.1464~1470 (2019)
46. Armstrong MJ, "Progressive supranuclear palsy : an update", Curr Neurol Neurosci Rep, 18, pp.12~ (2018)
47. Coughlin DG, "Progressive supranuclear palsy : advances in diagnosis and management", Parkinsonism Relat Disord, 73, pp.105~116 (2020)
48. Höglinger GU, "Clinical diagnosis of progressive supranuclear palsy : the movement disorder society criteria", Mov Disord, 32, pp.853~864 (2017)
49. Litvan I, "Clinical research criteria for the diagnosis of progressive supranuclear palsy(Steele-Richardson-Olszewski syndrome) : report of the NINDS-SPSP international workshop", Neurology, 47, pp.1~9 (1996)
50. Williams DR, "Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy : Richardson’s syndrome and PSP-parkinsonism", Brain, 128(Pt 6), pp.1247~1258 (2005)
51. Respondek G, "The phenotypic spectrum of progressive supranuclear palsy : a retrospective multicenter study of 100 definite cases", Mov Disord, 29, pp.1758~1766 (2014)
52. Helen Ling, "Clinical Approach to Progressive Supranuclear Palsy", Journal Of Movement Disorders, 9(1), pp.3~13 (2016), 대한파킨슨병및이상운동질환학회[DOI]
53. Shoichiro Ando, "Progressive supranuclear palsy with predominant cerebellar ataxia", Journal Of Movement Disorders, 13(1), pp.20~26 (2020), 대한파킨슨병및이상운동질환학회[DOI]
54. Boxer AL, "Advances in progressive supranuclear palsy : new diagnostic criteria, biomarkers, and therapeutic approaches", Lancet Neurol, 16, pp.552~563 (2017)
55. Eckert T, "FDG PET in the differential diagnosis of parkinsonian disorders", Neuroimage, 26, pp.912~921 (2005)
56. Papp MI, "Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy(striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome)", J Neurol Sci, 94, pp.79~100 (1989)
57. Vidailhet M, "Clinical diagnostic criteria for multiple system atrophy", Rev Neurol(Paris), 154, pp.17~21 (1998)
58. Gilman S, "Second consensus statement on the diagnosis of multiple system atrophy", Neurology, 71, pp.670~676 (2008)
59. Hirohisa Watanabe, "Clinical and imaging features of multiple system atrophy: Challenges for early and clinically definite diagnosis", Journal Of Movement Disorders, 11(3), pp.107~120 (2018), 대한파킨슨병및이상운동질환학회
60. Sakakibara R, "Urinary dysfunction and orthostatic hypotension in multiple system atrophy : which is the more common and earlier manifestation?", J Neurol Neurosurg Psychiatry, 68, pp.65~69 (2000)
61. Du JJ, "Clinical characteristics and quality of life in Chinese patients with multiple system atrophy", Brain Behav, 8, pp.e01135~ (2018)
62. Seppi K, "Progression of parkinsonism in multiple system atrophy", J Neurol, 252, pp.91~96 (2005)
63. Boesch SM, "Dystonia in multiple system atrophy", J Neurol Neurosurg Psychiatry, 72, pp.300~303 (2002)
64. Lin DJ, "Multiple system atrophy of the cerebellar type : clinical state of the art", Mov Disord, 29, pp.294~304 (2014)
65. Stankovic I, "A critique of the second consensus criteria for multiple system atrophy", Mov Disord, 34, pp.975~984 (2019)
66. Kaindlstorfer C, "Tremor in multiple system atrophy - a review", Tremor Other Hyperkinet Mov (N Y), 3 (2013)
67. Iranzo A, "Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder : an observational cohort study", Lancet Neurol, 12, pp.443~453 (2013)
68. Gilman S, "Consensus statement on the diagnosis of multiple system atrophy", J Neurol Sci, 163, pp.94~98 (1999)
69. Köllensperger M, "Red flags for multiple system atrophy", Mov Disord, 23, pp.1093~1099 (2008)
70. Lee PH, "A randomized trial of mesenchymal stem cells in multiple system atrophy", Ann Neurol, 72, pp.32~40 (2012)
71. Kim HN, "Feasibility and efficacy of intra-arterial administration of mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy", Stem Cells Transl Med, 6, pp.1424~1433 (2017)
72. Osaki Y, "Identification of a pre-possible multiple system atrophy phase", Acta Neurol Scand, 143, pp.313~317 (2021)
73. Dickson DW, "Office of Rare Diseases neuropathologic criteria for corticobasal degeneration", J Neuropathol Exp Neurol, 61, pp.935~946 (2002)
74. Kouri N, "Corticobasal degeneration : a pathologically distinct 4R tauopathy", Nat Rev Neurol, 7, pp.263~272 (2011)
75. Wadia PM, "The many faces of corticobasal degeneration", Parkinsonism Relat Disord, 13(Suppl 3), pp.S336~S340 (2007)
76. Boeve BF, "The multiple phenotypes of corticobasal syndrome and corticobasal degeneration : implications for further study", J Mol Neurosci, 45, pp.350~353 (2011)
77. Armstrong MJ, "Criteria for the diagnosis of corticobasal degeneration", Neurology, 80, pp.496~503 (2013)
78. Ling H, "Does corticobasal degeneration exist? A clinicopathological re-evaluation", Brain, 133(Pt 7), pp.2045~2057 (2010)
79. Kompoliti K, "Clinical presentation and pharmacological therapy in corticobasal degeneration", Arch Neurol, 55, pp.957~961 (1998)
80. Constantinescu R, "Levodopa responsiveness in disorders with parkinsonism : a review of the literature", Mov Disord, 22, pp.2141~2148 (2007)
81. Grisoli M, "MRI in corticobasal degeneration", Eur J Neurol, 2, pp.547~552 (1995)
82. Wenning GK, "Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination", J Neurol Neurosurg Psychiatry, 64, pp.184~189 (1998)
83. Wenning GK, "Prevalence of movement disorders in men and women aged 50-89years(Bruneck Study cohort) : a population-based study", Lancet Neurol, 4, pp.815~820 (2005)
84. 신혜원, "Drug-Induced Parkinsonism", Journal of Clinical Neurology, 8(1), pp.15~21 (2012), 대한신경과학회
85. Esper CD, "Failure of recognition of drug-induced parkinsonism in the elderly", Mov Disord, 23, pp.401~404 (2008)
86. Jones HM, "Dopamine and antipsychotic drug action revisited", Br J Psychiatry, 181, pp.271~275 (2002)
87. FP-CIT positron emission tomography, "Neurol Sci", 2015, 269~274
88. Hong JY, "Persistent drug-induced parkinsonism in patients with normal dopamine transporter imaging", PLoS One, 11, pp.e0157410~ (2016)
89. Mostile G, "Vascular parkinsonism : still looking for a diagnosis", Front Neurol, 9, pp.411~ (2018)
90. FitzGerald PM, "Lower body parkinsonism : evidence for vascular etiology", Mov Disord, 4, pp.249~260 (1989)
91. Korczyn AD, "Vascular parkinsonism--characteristics, pathogenesis and treatment", Nat Rev Neurol, 11, pp.319~326 (2015)
92. Rektor I, "Vascular parkinsonism--an update", J Neurol Sci, 248, pp.185~191 (2006)
93. Vizcarra JA, "Vascular Parkinsonism : deconstructing a syndrome", Mov Disord, 30, pp.886~894 (2015)
94. Rektor I, "An updated diagnostic approach to subtype definition of vascular parkinsonism-Recommendations from an expert working group", Parkinsonism Relat Disord, 49, pp.9~16 (2018)
95. Levin OS, "Correspondence relating to"an updated diagnostic approach to subtype definition of vascular parkinsonism-Recommendations from an expert working group"", Parkinsonism Relat Disord, 52, pp.109~110 (2018)
96. Frank E, "Normal-pressure hydrocephalus : clinical symptoms, diagnosis, pathophysiology, and treatment", Heart Lung, 11, pp.321~326 (1982)
97. Nassar BR, "Idiopathic normal pressure hydrocephalus : a review for general practitioners", Gerontol Geriatr Med, 2, pp.2333721416643702~ (2016)
98. Curran T, "Parkinsonian syndromes associated with hydrocephalus : case reports, a review of the literature, and pathophysiological hypotheses", Mov Disord, 9, pp.508~520 (1994)
99. Molde K, "Parkinsonian symptoms in normal pressure hydrocephalus : a population-based study", J Neurol, 264, pp.2141~2148 (2017)
100. Bugalho P, "Gait dysfunction in Parkinson’s disease and normal pressure hydrocephalus: a comparative study", J Neural Transm(Vienna), 120, pp.1201~1207 (2013)
101. Stolze H, "Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson’s disease", J Neurol Neurosurg Psychiatry, 70, pp.289~297 (2001)
102. Espay AJ, "Deconstructing normal pressure hydrocephalus : ventriculomegaly as early sign of neurodegeneration", Ann Neurol, 82, pp.503~513 (2017)
103. Halperin JJ, "Practice guideline : idiopathic normal pressure hydrocephalus : response to shunting and predictors of response : report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology", Neurology, 85, pp.2063~2071 (2015)
104. Pujari S, "Normal pressure hydrocephalus : long-term outcome after shunt surgery", J Neurol Neurosurg Psychiatry, 79, pp.1282~1286 (2008)
105. Ohara M, "Progressive supranuclear palsy often develops idiopathic normal pressure hydrocephalus-like magnetic resonance imaging features", Eur J Neurol, 27, pp.1930~1936 (2020)
106. Constantinides VC, "Midbrain morphology in idiopathic normal pressure hydrocephalus : a progressive supranuclear palsy mimic", Acta Neurol Scand, 141, pp.328~334 (2020)
107. Cabral D, "Frequency of Alzheimer’s disease pathology at autopsy in patients with clinical normal pressure hydrocephalus", Alzheimers Dement, 7, pp.509~513 (2011)

관련 논문AI추천